-
AO/PI Double Staining Kit for Cell Viability
2026-09-02
The AO/PI Double Staining Kit provides a rapid visual readout that separates viable, apoptotic, and necrotic populations in one fluorescent cell staining workflow. This guide translates the method into practical workflows for drug screening, organoid studies, and rare-cell profiling while emphasizing controls, imaging discipline, and troubleshooting.
-
Sodium Selenite, ROS, and Cervical Cancer Metabolism
2026-09-02
The reference study identifies a mechanistic link between sodium selenite–induced oxidative stress and suppression of glucose metabolic reprogramming in cervical cancer cells. Its combination of metabolic measurements, pathway perturbation, apoptosis analysis, and xenograft validation provides a useful framework for evaluating redox-active anticancer compounds.
-
Solanesol B8776: Practical Research Workflow
2026-09-01
Solanesol (B8776) provides a defined hydrophobic polyisoprenoid alcohol for workflows that require controlled handling of a poorly water-soluble compound. This guide covers DMSO stock preparation, fresh-solution use, vehicle controls, and QC, while clarifying that it is not suitable for water- or ethanol-only systems or diagnostic and medical use.
-
LLY-507: A Practical SMYD2 Inhibitor Workflow
2026-09-01
LLY-507 is a selective SMYD2 inhibitor for connecting target engagement with cancer-cell and fibrosis phenotypes. This workflow covers dosing, methylation assays, proliferation and apoptosis readouts, cross-domain interpretation, and troubleshooting for reproducible preclinical studies.
-
ONX-0914 (PR-957) for Immune Assays
2026-08-31
ONX-0914 (PR-957) enables selective LMP7-focused experiments that connect cytokine regulation with proteasome-dependent immune signaling. This practical guide covers PBMC assays, autoimmune disease workflows, and a carefully bounded extension into HIV-1 Nef–STAT1 research.
-
Alda 1: ALDH2 Activator for Cardiac Research
2026-08-31
Alda 1 is an ALDH2 activator that increases activity in both ALDH2*1 and the impaired ALDH2*2 variant. Preclinical studies connect ALDH2 activation with aldehyde detoxification, cardioprotection in ischemia, pressure-overload heart-failure delay, and radiation-induced dermatitis mitigation.
-
L-Glutathione Reduced in Translational Redox Research
2026-08-30
L-Glutathione Reduced provides a mechanistically grounded way to interrogate redox buffering, GST activity, and oxidative stress in translational workflows. By connecting reduced glutathione biology with GOT1-driven pancreatic cancer metabolism, this article outlines how researchers can use the reagent as a controlled probe, benchmark, and assay component without confusing redox rescue with therapeutic efficacy.
-
Full-Length αvβ3 Integrin Structures by Cryo-EM
2026-08-29
This study uses extensive cryo-EM analysis to define the conformational diversity of full-length human αvβ3 integrin in apo and ligand-bound states. Its discovery of previously uncharacterized intermediates and distinct CWHM-12-bound states provides a structural framework for understanding integrin activation and designing more selective inhibitors.
-
BIIE 0246: Neuropeptide Y Y2 Receptor Antagonist
2026-08-28
BIIE 0246 is a selective neuropeptide Y Y2 receptor antagonist with nanomolar affinity for Y2R-associated PYY3-36 binding sites. Its validated research uses include NPY Y2 receptor inhibition, presynaptic inhibitory effect blockade, feeding behavior modulation, and investigation of anxiolytic-like behavior.
-
Acifran: A Receptor-Resolved Assay Strategy
2026-08-28
Acifran is a research tool for dissecting HCAR2/GPR109A and HCAR3/GPR109B signaling in lipid metabolism. This article translates recent cryo-EM and cAMP findings into a practical, receptor-resolved framework for assay design, compound handling, and data interpretation.
-
Hexa His Tag Peptide: Cleaner, Smarter Protein IP
2026-08-27
Hexa His tag peptide enables selective competitive elution in antibody-based His-tagged protein workflows. This article connects its assay utility with new CARMIL membrane-binding evidence to improve purification design, interaction analysis, and interpretation of membrane-reconstituted experiments.
-
GSK126 EZH2 Inhibitor: Workflow & Applications
2026-08-27
GSK126 is a selective EZH2 inhibitor for connecting PRC2-driven H3K27me3 loss with gene reactivation, cancer-cell response, and combination-treatment design. This workflow also shows how findings from endothelial dysfunction research can inform, but not replace, oncology-focused validation.
-
Bortezomib (PS-341) Assay Workflows
2026-08-26
Build more informative Bortezomib response experiments by separating growth inhibition from true cell killing. This workflow combines reversible 20S proteasome inhibition with time-resolved viability and apoptosis measurements for stronger interpretation across cancer models.
-
Isoprenaline Hydrochloride in Heart–Brain Models
2026-08-26
Isoprenaline Hydrochloride, also known as isoproterenol, provides a controllable way to activate β1- and β2-adrenergic signaling across cardiac, vascular, respiratory, and neurobehavioral assays. This guide translates published heart–brain findings into practical workflows, controls, and troubleshooting decisions for model development.
-
LLY-507 SMYD2 Inhibitor: Assay Workflows
2026-08-25
LLY-507 combines nanomolar biochemical potency with strong SMYD2 selectivity for target-engagement, cancer-cell, and fibrosis-model workflows. This practical guide connects p53 methylation, proliferation, apoptosis, and renal-fibrosis readouts while emphasizing formulation control and preclinical limitations.